Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 12/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863788 | 0.88 | TAS2R14 (0.56) | TAS2R14SLC22A12ARSIRT5MEN1 | |
| SCHEMBL9682036 | 0.87 | MAPT (0.65) | TAS2R14SLC22A12ARMEN1LMNA | |
| SCHEMBL28856011 | 0.82 | TAS2R14 (0.56) | TAS2R14SLC22A12ARMEN1LMNA | |
| SCHEMBL5247689 | 0.82 | TAS2R14 (0.60) | TAS2R14SLC22A12AR | |
| SCHEMBL4181431 | 0.81 | AR (0.67) | TAS2R14SLC22A12AR | |
| SCHEMBL5664793 | 0.81 | AR (0.55) | TAS2R14AR | |
| SCHEMBL17657877 | 0.81 | EPHX1 (0.69) | TAS2R14MEN1LMNAMAPTKMT2A | |
| SCHEMBL17658051 | 0.81 | BLM (0.63) | TAS2R14SLC22A12AR | |
| SCHEMBL4167081 | 0.80 | S1PR3 (0.52) | SLC22A12ARMEN1LMNAKMT2A | |
| SCHEMBL202386 | 0.79 | AR (0.52) | TAS2R14AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | TAS2R14 2597/4885SLC22A12 3343/4885AR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.